Abbott Targets Kremers Over Niaspan Clone

Law360, New York (June 4, 2012, 4:30 PM EDT) -- Abbott Laboratories on Friday continued its crusade to protect its cholesterol drug Niaspan by filing a lawsuit against Kremers Urban Pharmaceuticals Inc., accusing the company of infringing Abbott's patents through its efforts to market a generic version of the drug.

The drugmaker's Delaware federal court lawsuit alleges that Kremers is infringing a pair of patents utilized in Abbott's Niaspan product, and that the generics maker should be stopped before it can bring its copycat drug to market.

“If Kremers’s infringement of the [patents] is not enjoined,...
To view the full article, register now.